Difference between revisions of "Renal cell carcinoma, VHL-associated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "|Phase II" to "|Phase 2") |
|||
| Line 28: | Line 28: | ||
|[https://doi.org/10.1056/nejmoa2103425 Jonasch et al. 2021 (MK-6482-004)] | |[https://doi.org/10.1056/nejmoa2103425 Jonasch et al. 2021 (MK-6482-004)] | ||
|2018-2019 | |2018-2019 | ||
| − | | style="background-color:#91cf61" |Phase | + | | style="background-color:#91cf61" |Phase 2 (RT) |
|- | |- | ||
|} | |} | ||
Revision as of 18:03, 12 February 2022
| Section editor | |
|---|---|
 |
Ali Raza Khaki, MD Stanford University Palo Alto, CA  arkhaki
|
Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Belzutifan monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Jonasch et al. 2021 (MK-6482-004) | 2018-2019 | Phase 2 (RT) |
Targeted therapy
- Belzutifan (Welireg) 120 mg PO once per day
Continued indefinitely
References
- MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains verified protocol Pubmed NCT03401788